Jane de Lartigue, PhD

Articles

Uncommon EGFR Mutations Come Into Focus With Novel NSCLC Therapies

October 1st 2021

The understanding of EGFR signaling in non–small cell lung cancer continues to evolve, helping to spark the development of novel therapies for new patient populations with uncommon alterations.

Persistent Development of WEE1 Pathway Inhibitors Begins to Pay Off

July 16th 2021

The lead novel candidate, the WEE1 inhibitor adavosertib, has been tested in more than 50 completed or ongoing clinical studies but has yet to proceed to a phase 3 trial despite showing promising safety and efficacy as monotherapy and in combination with a range of other cancer therapies.

Emerging Immune Checkpoint Research Focuses on CD137

July 8th 2021

During the past decade, a growing number of PD-1/PD-L1 inhibitors gained FDA approval to treat a wide range of cancer types. Their stimulatory counterparts also emerged as sought-after anticancer targets but have proved much more challenging to manipulate therapeutically.

MET Inhibitors Find Their Niche in NSCLC

June 23rd 2021

Three-quarters of all cases of lung adenocarcinoma, the most common type of non–small cell lung cancer, are defined by oncogenic driver events involving receptor tyrosine kinase–orchestrated cellular signaling pathways.

CD20-Targeting Antibodies Are Shaping a New Landscape for B-Cell Cancers

June 16th 2021

Among the pioneering targets for antibody therapy was CD20, the pursuit of which ultimately led to the first FDA-approved mAb for cancer therapy, rituximab, and defined a new era in the management of B-cell malignancies.

Strategies for Targeting PI3K Proliferate

May 10th 2021

Frequently dysregulated in cancer cells, the PI3K pathway has long been a high-priority therapeutic target in oncology. However, initial efforts with pan–class I PI3K inhibitors were hampered by disappointing efficacy and substantial toxicity.

New Approaches Seek to Meet the Challenge of Graft-Vs-Host Disease

April 28th 2021

The curative potential of allogeneic hematopoietic stem cell transplantation for many hematologic malignancies is hindered by the frequent development of graft-vs-host disease, a potentially fatal complication resulting from a complex interaction between donor immune cells in the graft and the host’s immune system.

NK Cell–Targeting Strategies Come Into Their Own

April 16th 2021

Although anticancer therapies that leverage T cells have commanded the most attention in the immuno-oncology era of the past decade, strategies based on natural killer cells have recently emerged as attractive approaches.

A New Crop of ER-Targeting Agents Takes Root

April 2nd 2021

Although endocrine therapies have revolutionized the treatment of breast cancers driven by the estrogen receptor, the development of resistance remains a major challenge that limits long-term remission with currently available drugs.

Ki-67 Is Poised to Advance as a Biomarker in Early-Stage Breast Cancer

March 24th 2021

Although Ki-67 is a commonly used measure of cellular proliferation in breast cancer tissue, its utility as a biomarker for helping to guide therapy decisions has been clouded by technical and clinical questions.

Bad Company: Concurrent Mutations Define Unique Subsets of NSCLC

February 18th 2021

The identification of oncogenic driver mutations in non–small cell lung cancer to inform targeted therapy selection is the bedrock of clinical practice in this disease, with current estimates suggesting that more than half of patients harbor an actionable mutation.

RET Joins the Ranks of Actionable Targets in Precision Oncology

February 1st 2021

Over the past 2 decades, a growing number of targetable tumor-specific molecular alterations have been identified, ushering in the era of precision oncology. Now, alterations in the RET gene can be added to the list of druggable targets.

Novel Strategy Gains Traction Against HRAS-Mutant Cancers

January 14th 2021

Despite decades of research and drug development, however, the therapeutic utility of targeting RAS is limited to ruling out treatment with certain drugs in patients without RAS mutations.

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

NRG1 Fusions Hold Promise as Pan-tumor Target

November 17th 2020

The identification of chromosomal rearrangements that result in oncogenic gene fusions ushered in the era of molecularly targeted therapies in oncology.

NEDD8 Emerges as a Novel Target in Hematologic Malignancies

October 8th 2020

Investigators are developing a new way to target a key oncogenic mechanism that may prove to be an effective anticancer strategy, particularly against hematologic malignancies.

Interest Builds for Targeting TIGIT Checkpoint

September 15th 2020

TIGIT, an inhibitory immune checkpoint that plays a central role in limiting antitumor responses, is attracting robust interest in the research community as a novel target for combination therapies across a range of cancer types, particularly solid tumors.

New Era for Targeting HER2 Beckons in Breast Cancer and Beyond

September 3rd 2020

Precision medicine advancements are opening a new chapter in the development of anticancer therapies that target the HER2 pathway, resulting in 3 approvals for breast cancer in less than a year and raising hopes for attacking other cancer types.

Fresh Approaches May Be Key to Unlocking OX40 Checkpoint

August 21st 2020

Considerable efforts have focused on developing agonists of costimulatory receptors, including OX40.

HRD Testing Heralds a New Biomarker, but Questions Linger

August 5th 2020

Homologous recombination, one of the major mechanisms of defective DNA repair, has emerged as a bona fide therapeutic target, yet its optimal use as a biomarker for patient selection remains a clouded scientific question.